Skip to main content

2017

Pharming announces warrant exercises and conversions of its Ordinary Bonds into shares mostly through cashless exercise

Financial updates

Pharming Group N.V. today announced that since the release of its update regarding cashless and other warrant exercises and bond conversions on 10 August 2017, it has issued 12,548,663 new shares to holders of warrants who have exercised those warrants, and to holders of its ordinary convertible bonds due 2021 who have converted their Bonds into shares.

Read more

2016

Pharming Launches Rights Issue to raise €12.1 million as part of RUCONEST® North American Rights Acquisition Financing

Financial updates

Pharming Group N.V. announces the launch of a 1 for 7 Rights Issue of up to 58,943,624 shares to raise approximately €12.1 million to existing shareholders its financing plans to enable the completion of the acquisition of the North American commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”), as announced on 9 August 2016 (the “Transaction”).

Read more

Filters

  • Cookies: This website uses cookies Check the cookies page for more information Accept Decline